FDA warned Genetrace that its HIV dried blood spot self-collection kit is unapproved and misbranded.
What happened
FDA reviewed Genetrace’s website in January 2026 and found it offered an HIV serological diagnostic dried blood spot card self-collection kit for delivery to individuals to collect samples at home and ship them to laboratories for HIV testing. FDA said the kit has no approved premarket approval application (PMA) or approved investigational device exemption (IDE), and no required premarket notification (510(k)) was provided. FDA had previously written the firm on March 31, 2025 about offering such kits.
What FDA found
FDA says the kit is adulterated because it lacks an approved premarket approval application (PMA) or an approved investigational device exemption (IDE).
FD&C Act section 501(f)(1)(B), 21 U.S.C. 351(f)(1)(B); sections 515(a) and 520(g), 21 U.S.C. 360e(a), 360j(g)FDA says the kit is misbranded because Genetrace did not give FDA the required premarket notification before commercial distribution.
FD&C Act section 502(o), 21 U.S.C. 352(o); section 510(k), 21 U.S.C. 360(k)FDA says the kit has not been authorized for any use, including HIV serological diagnostic testing.
FDA says Genetrace has not submitted any premarket submission to FDA seeking authorization to market this kit.
What FDA wants
FDA asks Genetrace to immediately stop any activity that makes the HIV DBS self-collection kit misbranded or adulterated. Within 15 working days of receiving the letter, Genetrace must write to FDA with the steps taken, an explanation of how recurrence will be prevented, and supporting documents; if not complete, it must give the reason and a completion date.
Who should pay attention
- companies selling at-home diagnostic collection kits
- labs that receive self-collected samples for HIV testing
- distributors or brands offering HIV self-tests
This is a summary. Read the original letter on fda.gov.